Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
Condition: Arthritis, Rheumatoid
MeSH terms: Arthritis; Arthritis, Rheumatoid
Intervention: ABP 710; Infliximab
Intervention description: Administered by intravenous infusion; Administered by intravenous infusion
Intervention MeSH terms: Infliximab
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 558.0
Sex: All
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      The main purpose of the study was to compare rheumatoid arthritis symptom improvement in
      participants who were given ABP 710 to those who were given infliximab, 22 weeks after
      starting treatment.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Subject (man or woman) is ≥ 18 and ≤ 80 years old.

          -  Subject is diagnosed with rheumatoid arthritis (RA) as determined by meeting the 2010
             American College of Rheumatology (ACR)/European League Against Rheumatism
             classification criteria for RA.

          -  Subject has RA duration of at least 3 months.

          -  Subject has active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints (based on
             66/68 joint count excluding distal interphalangeal joints) at screening and baseline
             and at least 1 of the following at screening:

               -  erythrocyte sedimentation rate ≥ 28 mm/hr

               -  serum C-reactive protein > 1.0 mg/dL

          -  Subject has a positive rheumatoid factor or anti-cyclic citrullinated peptide at
             screening.

          -  Subject has taken methotrexate (MTX) for ≥ 12 consecutive weeks and is on a stable
             dose of oral or subcutaneous MTX 7.5 to 25 mg/week for ≥ 8 weeks before receiving the
             investigational product and is willing to remain on a stable dose throughout the
             study.

          -  For a subject on nonsteroidal anti-inflammatory drugs (NSAIDs) or low potency
             analgesics such as tramadol, Soma Compounds, Fioricet, or Fiorinal, the dose should be
             stable for ≥ 2 weeks before screening.

          -  For a subject on oral corticosteroids (≤ 10 mg prednisone or equivalent), the dose
             should be stable for ≥ 4 weeks before screening.

          -  Subject has no known history of active tuberculosis.

          -  Subject has a negative test for tuberculosis during screening defined as either:

               -  negative purified protein derivative (PPD) defined as < 5 mm of induration at 48
                  to 72 hours after test is placed OR

               -  negative Quantiferon test

          -  Subject with a positive PPD and a history of Bacillus Calmette-Guérin vaccination is
             allowed with a negative Quantiferon test.

          -  Subject with a positive PPD test (without a history of Bacillus Calmette-Guérin
             vaccination) or a subject with a positive or indeterminate Quantiferon test is allowed
             if they have all of the following:

               -  no symptoms of tuberculosis according to the worksheet provided by the sponsor,
                  Amgen Inc.

               -  documented history of adequate prophylaxis initiation before receiving
                  investigational product in accordance with local recommendations

               -  no known exposure to a case of active tuberculosis after most recent prophylaxis

        Exclusion Criteria:

          -  Subject has a history of prosthetic or native joint infection.

          -  Subject has an active infection or history of infections as follows:

               -  any active infection for which systemic anti-infectives were used within 28 days
                  before first dose of investigational product

               -  a serious infection, defined as requiring hospitalization or intravenous (IV)
                  anti-infective(s) within 8 weeks before the first dose of investigational product

               -  recurrent or chronic infections or other active infection that, in the opinion of
                  the investigator, might cause this study to be detrimental to the subject

          -  Subject has a positive blood test for human immunodeficiency virus (HIV).

          -  Subject has a positive hepatitis B surface antigen, hepatitis B core antibody, or
             hepatitis C virus antibody result at screening.

          -  Subject has uncontrolled, clinically significant systemic disease such as diabetes
             mellitus, cardiovascular disease including moderate or severe heart failure (New York
             Heart Association Class III/IV), renal disease, liver disease, or hypertension.

          -  Subject had a malignancy within 5 years EXCEPT for treated and considered cured
             cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast
             ductal carcinoma.

          -  Subject has a history of neurologic symptoms suggestive of central or peripheral
             nervous system demyelinating disease.

          -  Subject has a major chronic inflammatory disease or connective tissue disease other
             than RA, with the exception of secondary Sjögren's syndrome.

          -  Subject has a concurrent medical condition that, in the opinion of the investigator,
             could cause this study to be detrimental to the subject.

          -  Subject has laboratory abnormalities at screening, including any of the following:

               -  hemoglobin < 9 g/dL

               -  platelet count < 100 000/mm³

               -  white blood cell count < 3 000/mm³

               -  aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x the upper
                  limit of normal

               -  creatinine clearance < 50 mL/min (Cockroft-Gault formula)

               -  any other laboratory abnormality, that, in the opinion of the investigator, will
                  prevent the subject from completing the study or will interfere with the
                  interpretation of the study results.

          -  Subject has used commercially available or investigational biologic therapies for RA
             as follows:

               -  anakinra, etanercept within 1 month before the first dose of investigational
                  product

               -  abatacept, tocilizumab, adalimumab, golimumab, certolizumab within 3 months
                  before the first dose of investigational product

               -  other experimental or commercially available biologic therapies for RA within 3
                  months or 5 half-lives (whichever is longer) before the first dose of
                  investigational product

               -  rituximab within 9 months before the investigational product along with evidence
                  of incomplete B cell recovery

          -  Subject has received live vaccines within 28 days before the first dose of
             investigational product or plans to receive live vaccines during the course of the
             study.

          -  Subject has previously received Remicade® (infliximab) or a biosimilar of infliximab.

          -  Woman who is pregnant or breast feeding, or plans to become pregnant while enrolled in
             the study and for 6 months after the last dose of investigational product.

          -  Women of childbearing potential (ie, neither surgically sterile nor postmenopausal)
             and do not agree to use adequate contraception (eg, true abstinence, sterilization,
             birth control pills, Depo-Provera® [medroxyprogesterone] injections, or contraceptive
             implants) while on study and for 6 months after the last dose of investigational
             product.